Discovery and Targeting of the Signaling Controls of <i>PNPLA3</i> to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings

Discovery and Targeting of the Signaling Controls of <i>PNPLA3</i> to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging worldwide epidemics, projected to become the leading cause of liver transplants. The strongest genetic risk factor for NAFLD/NASH susceptibility and progression is a single-nucleotide polymorphism (SNP) i...

Full description

Bibliographic Details
Main Authors: Brian E. Schwartz, Vaishnavi Rajagopal, Cynthia Smith, Evan Cohick, Gavin Whissell, Mario Gamboa, Rutuja Pai, Alla Sigova, Iris Grossman, David Bumcrot, Kavitha Sasidharan, Stefano Romeo, Alfica Sehgal, Piero Pingitore
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cells
Subjects:
NASH
NAFLD
PNPLA3
momelotinib
CYT-387
ACVR1
Online Access:https://www.mdpi.com/2073-4409/9/10/2247

Internet

https://www.mdpi.com/2073-4409/9/10/2247

Similar Items